Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose

Christian Domingo, Klaus F. Rabe, David Price, Guy Brusselle, Michael E. Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Paul J. Rowe, Yamo Deniz, Juby A. Jacob-Nara, Amr Radwan


This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2023. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose

Christian Domingo¹, Klaus F. Rabe²,³, David Price⁴,⁵, Guy Brusselle⁶, Michael E. Wechsler⁷, Changming Xia⁸, Nami Pandit-Abid⁹, Rebecca Gall⁸, Paul J. Rowe⁹, Yamo Deniz⁸, Juby A. Jacob-Nara⁹ and Amr Radwan⁸

¹Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. ²LungenClinic Grosshansdorf (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany. ³Christian-Albrechts University (member of the DZL), ARCN, Kiel, Germany. ⁴Observational and Pragmatic Research Institute, Midview City, Singapore. ⁵Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. ⁶Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. ⁷Department of Medicine, National Jewish Health, Denver, CO, USA. ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. ⁹Sanofi, Bridgewater, NJ, USA.

Corresponding author: Dr Christian Domingo

Address: S.Pneumologia, planta primera, Edifici Taulí Nou, Corporació Sanitària Parc Taulí, Parc Tauli 1 08208 Sabadell

Phone: +34-937231010 (extension 29142)

Email: cdomingo@tauli.cat

Co-author emails:

Klaus F. Rabe: k.f.rabe@lungenclinic.de

David Price: dprice@opri.sg

Guy Brusselle: Guy.Brusselle@uzgent.be
Take home message

Long-term treatment with dupilumab reduces asthma exacerbations, improves lung function, symptom control and quality of life, and reduces oral corticosteroid (OCS) use in patients with OCS-dependent asthma regardless of baseline OCS dose.
**List of abbreviations**

AQLQ, Asthma Quality of Life Questionnaire

ACQ-5, 5-item Asthma Control Questionnaire

DPL, dupilumab

FEV₁, forced expiratory volume in 1 second

GINA, Global Initiative for Asthma

IgE, immunoglobulin E

IL, interleukin

OCS, oral corticosteroid(s)

PBO, placebo

PSBL, parent study baseline

q2w, once every 2 weeks

SE, standard error
Abstract

**Background** Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This *post hoc* analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg/day) on long-term outcomes of dupilumab treatment.

**Methods** Annualised severe asthma exacerbation rates, forced expiratory volume in 1 second (FEV$_1$), measures of asthma control and quality of life (QoL), and OCS dose were evaluated in patients from the phase 3 VENTURE trial with severe OCS-dependent asthma, further categorised by OCS dose ≤10 or >10 mg/day at parent study baseline (PSBL), who enrolled in TRAVERSE.

**Results** Dupilumab reduced the annualised exacerbation rate in VENTURE, and it remained low throughout TRAVERSE (0.202–0.265 [OCS ≤10 mg/day at PSBL] and 0.221–0.366 [OCS >10 mg/day at PSBL]). Improvements in pre-bronchodilator FEV$_1$, asthma control and QoL observed in VENTURE dupilumab patients were sustained throughout TRAVERSE. Patients on placebo during VENTURE showed rapid improvements in FEV$_1$ upon initiating dupilumab in TRAVERSE, which were sustained to the end of TRAVERSE. Reductions in OCS dose observed in VENTURE were maintained throughout TRAVERSE, with more than two-thirds of patients achieving reductions in OCS doses to ≤5 mg/day by TRAVERSE Week 48.

**Conclusions** Improvements in clinical outcomes and reductions in OCS dose with dupilumab observed in VENTURE were maintained throughout TRAVERSE, regardless of baseline disease severity. Patients who switched from placebo in VENTURE to dupilumab in TRAVERSE had improved clinical outcomes and reductions in OCS dose comparable to those given dupilumab in VENTURE.

**Keywords** Dupilumab, asthma, efficacy, oral corticosteroid, exacerbation, FEV$_1$
**Introduction**

Oral corticosteroids (OCS) are commonly used for asthma management, particularly in patients with severe or uncontrolled disease [1]. However, OCS use is associated with increased risk of both acute adverse events and chronic adverse effects, including metabolic, bone- and muscle-related, cardiovascular and psychiatric complications [2, 3]. Recent guidelines emphasise prioritising strategies to avoid maintenance OCS use in patients with severe asthma unless all other treatment options have been exhausted [4]. Therapies that improve symptoms while providing durable reductions in OCS dose are therefore required.

Dupilumab, a fully human monoclonal antibody [5, 6], blocks the shared receptor component for interleukin (IL)-4 and IL-13, type 2 inflammatory cytokines implicated in numerous type 2 diseases ranging from asthma to atopic dermatitis [7–9], and thus inhibits their signalling. The OCS-sparing effect of dupilumab added to standard of care therapy in adults with OCS-dependent severe asthma was investigated in the phase 3 LIBERTY ASTHMA VENTURE study. At the end of the 24-week study, dupilumab significantly reduced OCS use while also reducing severe asthma exacerbation rates and improving pre-bronchodilator forced expiratory volume in 1 second (FEV$_1$) [10]. Overall safety was consistent with the known dupilumab safety profile.

The single-arm open-label LIBERTY ASTHMA TRAVERSE (NCT02134028) extension study evaluated the long-term efficacy, safety and tolerability of dupilumab in patients who had participated in a previous dupilumab asthma study, including VENTURE [11, 12]. In TRAVERSE, the safety and efficacy of dupilumab were maintained for up to an additional 96 weeks, and improvements in annualised exacerbation rates, lung function and asthma control were sustained or improved further in patients who received dupilumab during the parent studies and continued into TRAVERSE. Marked and sustained improvements in all outcome
measures were observed in patients who received placebo during the parent studies and initiated dupilumab in TRAVERSE [12].

This *post hoc* analysis of TRAVERSE aimed to determine the potential impact of baseline OCS dose on the long-term efficacy of dupilumab, and reduction in OCS use, in patients with severe OCS-dependent asthma who previously participated in VENTURE.
Methods

Study design

Full details of the VENTURE and TRAVERSE studies have been published previously [10, 12]. In brief, VENTURE (NCT02528214) was an international, randomised, double-blind, placebo-controlled, phase 3 trial assessing the efficacy and safety of dupilumab in patients ≥12 years of age with OCS-dependent asthma. Patients were randomised 1:1 to subcutaneous dupilumab 300 mg q2w for 24 weeks or matched placebo. During the 24-week treatment period, patients received an optimised OCS dose for 4 weeks followed by systematic dose reduction every 4 weeks over the next 16 weeks per protocol-defined algorithm; compliance was monitored at each visit. Further details of the protocol can be found in the primary VENTURE publication [10].

TRAVERSE (NCT02134028) was a multinational, multicentre, single-arm, open-label extension study that enrolled patients who had completed a previous phase 2 or 3 dupilumab asthma study [12]. All patients received 300 mg q2w for up to an additional 96 weeks. Following a protocol amendment due to the accumulation of safety data from clinical trials for dupilumab across multiple indications, the treatment period was reduced from 96 to 48 weeks. Patients enrolled from VENTURE entered TRAVERSE directly from the VENTURE end-of-treatment visit. On enrolment in TRAVERSE, patients were encouraged to continue their background OCS therapy regimen as maintained during VENTURE, and compliance was assessed as part of the efficacy endpoints. Modification of daily OCS dose was permitted at the discretion of the study investigator, but changes were not guided by a protocol-defined down-titration algorithm as in VENTURE [10, 12].

VENTURE and TRAVERSE were performed in accordance with the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonisation and
applicable regulatory requirements. Written informed consent was obtained from all patients before enrolment. Patients younger than 18 years of age provided assent according to the ethics committee-approved standard practice for paediatric patients at each participating centre. The protocol and informed consent or assent forms were approved by independent ethics committees and institutional review boards at the study sites.

Study population

Full inclusion and exclusion criteria of VENTURE and TRAVERSE have been published previously [10, 12]. This post hoc analysis included patients from VENTURE, stratified according to baseline OCS dose in VENTURE (≤10 mg/day or >10 mg/day), who enrolled in TRAVERSE. A cut-off of 10 mg/day was chosen as it was the median optimised OCS dose at VENTURE baseline. Patients who received dupilumab in VENTURE and continued to receive dupilumab in TRAVERSE were classified as the dupilumab/dupilumab group and patients who originally received placebo in VENTURE and received dupilumab in TRAVERSE as the placebo/dupilumab group.

Outcomes

Clinical efficacy endpoints included unadjusted annualised severe exacerbation rates over the treatment period (both VENTURE and up to TRAVERSE Week 96) and change from parent study baseline (PSBL) in pre-bronchodilator FEV₁, 5-item Asthma Control Questionnaire (ACQ-5) scores and Asthma Quality of Life Questionnaire (AQLQ) scores over time up to TRAVERSE Week 48.

OCS use assessment included the mean OCS dosage and mean cumulative OCS dose (total cumulative dose/number of days) during VENTURE and over a 48-week TRAVERSE
treatment period; the proportions of patients who achieved OCS use targets of <0 mg/day (only for eligible patients), ≤5 mg/day and <10 mg/day during VENTURE; and the proportion of these patients who maintained these reductions to TRAVERSE Week 48.

Statistical analysis

TRAVERSE was an open-label, single-arm extension study, and statistical analyses are therefore descriptive in nature. Continuous endpoints (change in OCS dose, change in pre-bronchodilator FEV₁, ACQ-5 and AQLQ over time) were calculated as means with standard error (SE). The unadjusted annualised exacerbation rates were computed as the total number of events during the observation period divided by the total exposure in patient-years in the observation period. Categorical endpoints are presented as percentages, with the number of patients with non-missing values at any time point as denominators.
**Results**

**Patients**

Overall, 121 patients with baseline OCS dose ≤10 mg/day (dupilumab/dupilumab: n=60; placebo/dupilumab: n=61) and 66 patients with baseline OCS dose >10 mg/day (dupilumab/dupilumab: n=30; placebo/dupilumab: n=36) were included in this analysis. Baseline characteristics were generally well balanced between groups (table 1).

**Annualised rate of severe exacerbations**

Dupilumab reduced severe exacerbation rates by 67% and 32% compared with placebo in VENTURE in patients with baseline OCS dose ≤10 and >10 mg/day, respectively. During the VENTURE study, greater annualised exacerbation rate reductions were seen in the dupilumab group versus the placebo group, irrespective of baseline OCS dose group (figure 1). The annualised exacerbation rate continued to progressively decrease in both OCS dose subgroups during TRAVERSE, with the dupilumab/dupilumab and placebo/dupilumab groups achieving comparable outcomes over the treatment period in patients with OCS ≤10 mg/day at PSBL. In the subgroup of patients with OCS >10 mg/day at PSBL, dupilumab also further reduced the annualised exacerbation rate compared with the parent study, although reductions in the placebo/dupilumab group were greater than those observed in the dupilumab/dupilumab group, which may be attributable in part to small patient numbers (figure 1).

**Pre-bronchodilator FEV₁**

The overall improvement in pre-bronchodilator FEV₁ seen with dupilumab in VENTURE was sustained during TRAVERSE irrespective of the baseline OCS dose, whilst patients switching from placebo to dupilumab showed rapid and marked improvements in FEV₁ during TRAVERSE (figure 2). By Week 48 of TRAVERSE, mean (SD) change from
baseline in FEV\textsubscript{1} in patients with PSBL OCS dose ≤10 mg/day was 0.35 (0.53) L in the dupilumab/dupilumab group and 0.35 (0.52) L in the placebo/dupilumab group (figure 2a). In patients with PSBL OCS dose >10 mg/day, mean (SD) change in FEV\textsubscript{1} from baseline to Week 48 of TRAVERSE was 0.30 (0.55) L in the dupilumab/dupilumab group and 0.25 (0.45) L in the placebo/dupilumab group (figure 2b).

\textit{Asthma control}

ACQ-5 showed an overall improvement from VENTURE baseline, with sustained reductions throughout the TRAVERSE study regardless of baseline OCS dose (figure 3a). In patients with PSBL OCS dose ≤10 mg/day, mean (SD) total ACQ-5 scores at VENTURE baseline were 2.39 (1.18) in the dupilumab/dupilumab group and 2.54 (1.14) in the placebo/dupilumab group. In patients with PSBL OCS dose >10 mg/day, mean (SD) total ACQ-5 scores at VENTURE baseline were 2.53 (1.05) in the dupilumab/dupilumab group and 2.69 (1.06) in the placebo/dupilumab group. At Week 0 of TRAVERSE, there was a greater improvement in mean (95% confidence interval [CI]) change from baseline in ACQ-5 in the dupilumab/dupilumab group (−1.05 [−1.34, −0.750]) compared with the placebo/dupilumab group (−0.44 [−0.76, −0.110]) in patients with PSBL OCS dose ≤10 mg/day; asthma control had improved in both treatment arms in patients with PSBL OCS dose >10 mg/day (figure 3a). These improvements were maintained in the dupilumab/dupilumab group in both OCS dose subgroups, with additional improvements seen in the placebo/dupilumab group, by Week 48 of TRAVERSE.

\textit{Asthma-related quality of life}

Overall, improvements in AQLQ scores seen during VENTURE were maintained through TRAVERSE regardless of baseline OCS dose (figure 3b). In patients with PSBL OCS dose
≤10 mg/day, mean (SD) AQLQ score at VENTURE baseline was 4.41 (1.08) in the dupilumab/dupilumab group and 4.43 (1.11) in the placebo/dupilumab group; in patients with PSBL OCS dose >10 mg/day the scores were 4.26 (1.26) in the dupilumab/dupilumab group and 4.19 (1.17) in the placebo/dupilumab group. By the end of VENTURE, mean (95% CI) change from baseline in AQLQ in the dupilumab/dupilumab group (1.05 [0.73, 1.36]) was greater than in the placebo/dupilumab group (0.42 [0.17, 0.68]) in patients with PSBL OCS dose ≤10 mg/day, and mean AQLQ score had improved in both treatment arms in patients with PSBL OCS dose >10 mg/day (figure 3b) These improvements were sustained in the dupilumab/dupilumab group, in both OCS dose subgroups, while further improvements were seen in the placebo/dupilumab groups, through to Week 48 of TRAVERSE.

OCS use

Over the course of the VENTURE study, mean OCS use decreased in both the dupilumab and placebo arms, following study protocol, with a significantly greater percent reduction in the dupilumab group irrespective of baseline OCS dose (figure 4). Reduction in OCS use with dupilumab persisted through TRAVERSE in both the dupilumab/dupilumab and placebo/dupilumab groups, across the two baseline OCS dose groups, where no OCS-sparing protocol was provided and the decision to reduce OCS was at the treating physician’s discretion.

In patients with PSBL OCS dose ≤10 mg/day, mean (SD) daily OCS dose was 1.60 (2.85) mg/day in the dupilumab/dupilumab group and 4.80 (4.50) mg/day in the placebo/dupilumab group at TRAVERSE Week 0, falling to 1.06 (1.87) and 4.35 (3.98) mg/day, respectively, at Week 48 (figure 4). In patients with PSBL OCS dose >10 mg/day, mean (SD) daily OCS dose was 6.17 (7.95) mg/day in the dupilumab/dupilumab group and 9.10 (9.18) mg/day in
the placebo/dupilumab group at TRAVERSE Week 0, and 4.58 (4.72) and 6.06 (6.49) mg/day, respectively, at Week 48 (figure 4). Overall OCS dose reductions from PSBL were 83% and 50% in patients with PSBL OCS dose ≤10 mg/day, and 75% and 66% in patients with PSBL OCS dose >10 mg/day, in the dupilumab/dupilumab and placebo/dupilumab groups, respectively, by TRAVERSE Week 48 (figure 4).

Mean cumulative OCS dose and mean daily dose were markedly higher in placebo/dupilumab-treated patients compared with dupilumab/dupilumab-treated patients regardless of OCS dose subgroup in both VENTURE and TRAVERSE (table 2).

Mean (SD) daily dose in patients with PSBL OCS ≤10 mg/day, who had Week 48 data available, was 3.14 (1.56) mg in the dupilumab/dupilumab group and 5.37 (2.35) mg in the placebo/dupilumab group during VENTURE, and 1.15 (2.25) mg versus 4.42 (3.94) mg, respectively, during TRAVERSE. In patients with PSBL OCS >10 mg/day who had Week 48 data available, mean (SD) daily OCS dose was 10.78 (4.70) mg in the dupilumab/dupilumab group and 11.34 (5.39) mg in the placebo/dupilumab group during VENTURE, and 4.94 (5.32) mg versus 6.10 (6.54) mg, respectively, during TRAVERSE.

Similar reductions were observed in median OCS dose (figure 4b). In line with the observation for the daily mean OCS dose, median OCS dose was also markedly lower in the dupilumab/dupilumab group compared with the placebo/dupilumab group regardless of OCS dose subgroup in both VENTURE and TRAVERSE.

The proportion of all patients achieving clinically relevant OCS dose thresholds of 0 mg/day, ≤5 mg/day and <10 mg/day during VENTURE and TRAVERSE are shown in figure 5. The
analysis of patients who achieved the 0 mg/day OCS threshold in VENTURE (figure 5a) included only those who were eligible to achieve this during the study using the down-titration protocol in the time specified. Overall, data from TRAVERSE are consistent with those from VENTURE, in which patients reduced OCS dose according to a protocol-defined algorithm.

Of patients who had achieved an OCS dose threshold at the end of VENTURE, a majority maintained it through to Week 48 of TRAVERSE (figure 6).

*Effect of OCS dose on clinical efficacy*

In all patients from VENTURE who enrolled in TRAVERSE (i.e., patients with PSBL OCS ≤10 mg/day and patients with PSBL OCS >10 mg/day) the interaction between treatment and VENTURE baseline OCS dose across the clinical efficacy outcomes analysed (annualised severe asthma exacerbation rates, and change from PSBL in FEV₁, ACQ-5, AQLQ, and OCS dose) was not significant (P value for interaction > 0.05) up to TRAVERSE Week 96.
Discussion

This analysis demonstrated that reductions in annualised exacerbation rates and lung function improvements seen with dupilumab in VENTURE [10, 13] continued through TRAVERSE and were consistent in patients who received an OCS dose ≤10 mg/day or >10 mg/day at baseline, with patients in the placebo/dupilumab group (who first initiated dupilumab in TRAVERSE) achieving improvements in both clinical measures comparable with the dupilumab/dupilumab group, irrespective of baseline OCS dose. Dupilumab also maintained improvements in asthma control and quality of life in VENTURE through TRAVERSE regardless of baseline OCS dose. Assessment of dupilumab’s effectiveness across OCS dose levels at PSBL showed similar treatment effects across the endpoints included in this analysis, suggesting that OCS dose level does not have an impact on dupilumab’s efficacy.

These clinical improvements were seen despite persistent reductions in OCS use, which were greater in the dupilumab/dupilumab group compared to the placebo/dupilumab group by the end of TRAVERSE, both in patients with baseline OCS dose above and below the median. This demonstrates the persistent and incremental benefit of OCS dose reduction when maintaining dupilumab treatment over time. For the dupilumab group during VENTURE around two-thirds of patients with baseline OCS dose ≤10 mg/day and over a quarter of patients with baseline OCS dose >10 mg/day were able to completely discontinue OCS use following the OCS-sparing strategy as per study protocol [10]. Modification of OCS dose was not mandated in the TRAVERSE protocol but at the investigators’ discretion, which is reflective of the real-world scenario. Despite this there were, for the most part, incremental improvements in the percentage of patients achieving 0, ≤5 and <10 mg/day OCS dose by Week 48 of TRAVERSE in both OCS dose subgroups within each treatment arm.

When interpreting these data it should be noted that investigators may have concerns regarding adrenal insufficiency [14, 15] and there is currently no consensus on whether to reduce maintenance OCS dose in this context. However, there is consensus that – in situations where OCS maintenance treatment is required (e.g. uncontrolled asthma despite optimised GINA 5 treatment steps) – OCS doses below ≤5 mg/day are acceptable, but annual cumulative OCS doses should be closely monitored as a marker for asthma control [16].
There are increasing risks of acute and chronic complications with cumulative OCS exposure (including bone, respiratory, cardiovascular, renal, eye and neurological disorders) [1], with a clear dose–response relationship between outcomes and cumulative OCS exposure [17]. Importantly, onset of some outcomes is seen with a cumulative OCS dose exposure of between 500 and <1000 mg, with risk increasing substantially above 1000 mg [17]. In TRAVERSE, we have demonstrated that delaying treatment can result in cumulative doses up to four times greater, as seen in the placebo/dupilumab group when compared with the dupilumab/dupilumab group. Thus, in this patient population earlier treatment with dupilumab is warranted to reduce overall OCS dose exposure and the resulting side effects.

Our findings suggest that active, guided management of OCS dose may be required to encourage OCS dose reductions if goals of “oral steroid stewardship” [18, 19] or complete avoidance of OCS in patients with asthma are to be achieved [4, 16, 20, 21]. A lack of asthma-specific algorithms for OCS dose reduction and guidelines for systematic screening of adverse events have been cited as potential barriers to reducing OCS exposure [20]. Hesitancy to reduce OCS dose in patients with severe asthma may mean that the opportunity to improve outcomes by reducing the risk of OCS-related adverse events is missed. Clinical studies of biologics in asthma have used different tapering algorithms for OCS-sparing regimens [10, 22–25], emphasising a need for clinical guidelines in routine practice.

The limitations of this study are inherent to its design. All analyses were post hoc and as TRAVERSE was a single-arm open-label study, statistical analyses were descriptive only. Furthermore, as is common with extension studies, patients were enrolled on a voluntary basis and only patients who completed the parent study were eligible to participate. This
could potentially have introduced a treatment bias towards patients who received active
treatment during the parent study. In addition, following a protocol amendment the treatment
period was reduced from 96 to 48 weeks; therefore, for some analyses only 48-week data
were available. The optimal OCS dose cut-off for subgroup stratification could be debated –
we chose the median optimised baseline dose of 10 mg/day at VENTURE baseline.
Rheumatology guidelines propose a cut-off of 7.5 mg daily OCS dose to optimise
antiresorptive treatment [26, 27]. Thus, a cut-off 10 mg was justifiable from a clinical
standpoint. Finally, the extent to which adrenal suppression influenced patients’ ability to
reduce their OCS dose is unclear.

An evaluation of the VENTURE and TRAVERSE studies combined has shown that long-
term dupilumab treatment provided sustained efficacy in adult and adolescent patients with
OCS-dependent severe asthma while allowing for significant reductions in OCS dose,
regardless of baseline OCS starting dose.
Acknowledgements: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc.

ClinicalTrials.gov identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Êilis Sutton, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice Guideline.

Author contributions: C. Xia, N. Pandit-Abid, R. Gall, P.J. Rowe, Y. Deniz, J.A. Jacob-Nara and A. Radwan contributed to project concept, study design and study implementation; C. Domingo, G. Brusselle and M.E. Wechsler contributed to data collection; C. Xia contributed to data and statistical analysis; all authors, including K.F. Rabe, and D. Price, contributed to data analysis and interpretation and manuscript editing; all authors critically reviewed and approved the final version of the manuscript.

Data sharing: Qualified researchers may request access to patient-level data and related study documents, including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan and dataset specifications. Patient-level data will be anonymised and study documents will be redacted to protect the privacy of our trial participants. Further details on Sanofi’s data sharing criteria, eligible studies and process for requesting access can be found at: https://www.vivli.org

Conflict of interest: C. Domingo reports travel and speaker fees from ALK, Allergy Therapeutics, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline (GSK), HAL Allergy, ImmunoTek, Menarini, Novartis, Pfizer, sanofi-aventis, Stallergenes Greer, and Teva. K.F. Rabe reports consultant and speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi and Teva. D. Price reports advisory board membership with
Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mundipharma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceuticals, Thermo Fisher Scientific and Viatris; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance Biopharma and Viatris; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceuticals, Theravance Biopharma, UK National Health Service and Viatris; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceuticals and Viatris; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Chiesi, CytoReason, Equillium, Genentech, Genzyme, Novartis, Pulmatrix, Regeneron Pharmaceuticals, Inc., resTORbio, Sentien Biotechnologies and Teva; and grants and personal fees from GSK and Sanofi. C. Xia, R. Gall, Y. Deniz and A. Radwan are employees of and shareholders in Regeneron Pharmaceuticals, Inc. N. Pandit-Abid, P.J. Rowe and J.A. G. Brusselle reports consultant and speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi and Teva. M.E. Wechsler reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, CytoReason, Equillium, Genentech, Genzyme, Novartis, Pulmatrix, Regeneron Pharmaceuticals, Inc., resTORbio, Sentien Biotechnologies and Teva; and grants and personal fees from GSK and Sanofi. G. Brusselle reports consultant and speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi and Teva. M.E. Wechsler reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, CytoReason, Equillium, Genentech, Genzyme, Novartis, Pulmatrix, Regeneron Pharmaceuticals, Inc., resTORbio, Sentien Biotechnologies and Teva; and grants and personal fees from GSK and Sanofi. C. Xia, R. Gall, Y. Deniz and A. Radwan are employees of and shareholders in Regeneron Pharmaceuticals, Inc. N. Pandit-Abid, P.J. Rowe and J.A.
Jacob-Nara are employees of Sanofi, and may hold stock and/or stock options in the company.
**TABLE 1** Baseline characteristics, disease characteristics and biomarkers at VENTURE baseline

<table>
<thead>
<tr>
<th></th>
<th>VENTURE baseline OCS dose ≤10 mg/day</th>
<th>VENTURE baseline OCS dose &gt;10 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO/DPL (n=61)</td>
<td>DPL/DPL (n=60)</td>
</tr>
<tr>
<td>Age, mean (SD), years</td>
<td>50.9 (12.0)</td>
<td>53.5 (12.0)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>26 (42.6)</td>
<td>25 (41.7)</td>
</tr>
<tr>
<td>Ongoing atopic or allergic condition, # n (%)</td>
<td>43 (70.5)</td>
<td>44 (73.3)</td>
</tr>
<tr>
<td>Former smoker, n (%)</td>
<td>13 (21.3)</td>
<td>16 (26.7)</td>
</tr>
<tr>
<td>OCS dose, mg/day, mean (SD)</td>
<td>8.07 (2.06)</td>
<td>7.42 (2.16)</td>
</tr>
<tr>
<td>Number of severe asthma exacerbations in the 1 year prior to parent study, mean (SD)</td>
<td>2.30 (2.19)</td>
<td>1.87 (2.17)</td>
</tr>
<tr>
<td>Pre-bronchodilator FEV₁, mean (SD), L</td>
<td>1.62 (0.66)</td>
<td>1.50 (0.48)</td>
</tr>
<tr>
<td>Pre-bronchodilator FEV₁, mean (SD), % predicted</td>
<td>51.6 (16.0)</td>
<td>51.6 (15.2)</td>
</tr>
<tr>
<td>FEV₁ reversibility, mean (SD), %</td>
<td>18.6 (25.2)</td>
<td>22.6 (26.4)</td>
</tr>
<tr>
<td>ACQ-5 score, mean (SD), scale 0–6</td>
<td>2.54 (1.14)</td>
<td>2.39 (1.18)</td>
</tr>
<tr>
<td>AQLQ global score, mean (SD), scale 1–7</td>
<td>4.43 (1.11)</td>
<td>4.41 (1.08)</td>
</tr>
<tr>
<td>Blood eosinophils, median (Q1–Q3), cells/µL</td>
<td>250 (110.0–430.0)</td>
<td>340 (180–545.0)</td>
</tr>
<tr>
<td>Total IgE, median (Q1–Q3), IU/mL</td>
<td>140.0 (36.0–494.5)</td>
<td>185.5 (103.5–484.5)</td>
</tr>
<tr>
<td>FeNO, median (Q1–Q3), ppb</td>
<td>21.0 (15.0–44.0)</td>
<td>28.0 (14.0–47.0)</td>
</tr>
</tbody>
</table>

ACQ-5: 5-item Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; DPL: dupilumab; FeNO: fractional exhaled nitric oxide; FEV₁: forced expiratory volume in 1 second; IgE: immunoglobulin E; OCS: oral corticosteroids; PBO: placebo; ppb: parts per billion; SD: standard deviation. #: A patient will be considered to have an atopic or allergic condition if the patient has any of the following diseases: atopic dermatitis, allergic conjunctivitis or rhinitis, eosinophilic oesophagitis, food allergy or hives, or if baseline total IgE ≥100 IU/mL and at least one aeroantigen-specific IgE is positive (≥0.35 IU/mL) at baseline.
<table>
<thead>
<tr>
<th></th>
<th>VENTURE baseline OCS dose ≤10 mg/day</th>
<th>VENTURE baseline OCS dose &gt;10 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO/DPL (n=51)</td>
<td>DPL/DPL (n=39)</td>
</tr>
<tr>
<td><strong>Cumulative OCS dose, mean (SD), mg</strong></td>
<td><strong>VENTURE (Weeks 0–24)</strong></td>
<td><strong>TRAVERSE (Weeks 0–48)</strong></td>
</tr>
<tr>
<td></td>
<td>911.4 (397.99)</td>
<td>532.1 (259.53)</td>
</tr>
<tr>
<td></td>
<td>2388.5 (2037.25)</td>
<td>584.9 (1118.65)</td>
</tr>
<tr>
<td><strong>Daily OCS dose, mean (SD), mg</strong></td>
<td><strong>VENTURE (Weeks 0–24)</strong></td>
<td><strong>TRAVERSE (Weeks 0–48)</strong></td>
</tr>
<tr>
<td></td>
<td>5.37 (2.35)</td>
<td>3.14 (1.55)</td>
</tr>
<tr>
<td></td>
<td>4.42 (3.94)</td>
<td>1.15 (2.25)</td>
</tr>
</tbody>
</table>

DPL: dupilumab; PBO: placebo; OCS: oral corticosteroid; SD: standard deviation.
References


Figure Legends

FIGURE 1  Unadjusted annualised rate of severe asthma exacerbations in the patients with OCS dose ≤10 mg/day and >10 mg/day at VENTURE baseline. DPL: dupilumab; OCS: oral corticosteroid; PBO: placebo; PSBL: parent study baseline; q2w: once every 2 weeks. #: The total number of events that occurred during the treatment period divided by the total number of patient-years followed in the treatment period.

FIGURE 2  Change over time in mean (± SE) pre-bronchodilator FEV₁ from PSBL in patients with OCS dose a) ≤10 mg/day OCS and b) >10 mg/day at PSBL. BD: bronchodilator; FEV₁: forced expiratory volume in 1 second; L: litre; OCS: oral corticosteroid; PSBL: parent study baseline; q2w: once every 2 weeks; SD: standard deviation; SE: standard error.

FIGURE 3  Mean (95% CI) change in a) asthma control (as measured by ACQ-5 scores) and b) asthma-related quality of life (as measured by AQLQ scores) during TRAVERSE in patients with OCS dose ≤10 mg/day and >10 mg/day at PSBL. ACQ-5: 5-item Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; CI: confidence interval; DPL: dupilumab; OCS: oral corticosteroid; PBO: placebo; PSBL: parent study baseline; q2w: once every 2 weeks.

FIGURE 4  a) Change from PSBL in mean (± SE) OCS dose and b) median (Q1–Q3) change of OCS dose at Week 48 of TRAVERSE in patients with OCS dose ≤10 mg/day OCS and >10 mg/day at PSBL. OCS: oral corticosteroid; PSBL: parent study baseline; Q: quartile; q2w: once every 2 weeks; SE: standard error.
FIGURE 5 Proportion of patients who achieved OCS dose targets during VENTURE and TRAVERSE by VENTURE baseline OCS dose a) 0 mg/day, b) ≤5 mg/day and c) <10 mg/day. Analysis of patients who achieved the 0 mg/day OCS threshold in VENTURE included only those who were eligible to achieve this during the study using the down-titration protocol in the time specified. OCS: oral corticosteroid; PSBL: parent study baseline; q2w: once every 2 weeks.

FIGURE 6 Proportion of patients who achieved OCS dose targets during VENTURE and maintained targets during TRAVERSE by VENTURE baseline OCS dose a) 0 mg/day, b) ≤5 mg/day and c) <10 mg/day. Analysis of patients who achieved the 0 mg/day OCS threshold in VENTURE included only those who were eligible to achieve this during the study using the down-titration protocol in the time specified. OCS: oral corticosteroid; PSBL: parent study baseline; q2w: once every 2 weeks.
Figure 1
Figure 2
Figure 3
Figure 4

(a) Patients with ≤10 mg/day OCS dose at PSBL.

(b) Patients with >10 mg/day OCS dose at PSBL.

Legend:
- Placebo (VENTURE) and Dupilumab (TRAVELER)
Figure 5
Figure 6
How does OCS dose at study baseline impact outcomes of dupilumab treatment in patients with OCS-dependent severe asthma in the long-term, and how does it impact OCS tapering in those patients?

Hello. I’m Christian Domingo and on behalf of my co-authors, I would like to present the results from our evaluation of dupilumab efficacy and OCS dose in patients with OCS-dependent severe asthma in the LIBERTY ASTHMA TRAVERSE study.

Approximately 45% of patients with severe asthma require OCS long-term to control their symptoms, which can be associated with considerable negative side effects.

TRAVERSE, a phase 3, single-arm, open-label extension study, showed that dupilumab treatment up to 96 weeks led to sustained efficacy, with a safety profile consistent with that observed in parent studies. This analysis included patients who previously completed the LIBERTY ASTHMA VENTURE study and subsequently enrolled in TRAVERSE.

The data presented here are an extension of the previously published VENTURE study, where, in patients with OCS-dependent severe asthma, dupilumab treatment reduced OCS whilst decreasing severe exacerbations and improving lung function.

187 patients from VENTURE enrolled in TRAVERSE and received add-on dupilumab 300 mg every 2 weeks for up to 96 weeks, with no specific OCS tapering instructions given to physicians for TRAVERSE. Of the 187 patients included, 90 continued with dupilumab 300 mg given every 2 weeks and will be referred to as the dupilumab/dupilumab group; 97 patients, who were on placebo during the parent study and initiated dupilumab at the beginning of TRAVERSE will be referred to as the placebo/dupilumab group. Patients were further stratified by their OCS dose at parent study baseline to 10 mg or less per day and those who needed more than 10 mg per day.

Reductions in severe exacerbation rates observed in the parent study were maintained throughout TRAVERSE in the patients on dupilumab during VENTURE, regardless of baseline OCS dose as shown in the light blue bars. Patients on placebo during VENTURE showed rapid and sustained reductions throughout TRAVERSE as shown in the gray and purple bars.

Similarly, improvements observed in pre-bronchodilator FEV₁ during the parent study were sustained throughout TRAVERSE in the dupilumab/dupilumab group up to Week 48, as can be seen by the blue line. Pre-bronchodilator FEV₁ also rapidly improved, and was sustained throughout TRAVERSE, in the placebo/dupilumab group, regardless of baseline OCS dose.

Improvements in asthma control, as measured by reductions in ACQ-5 scores, and asthma-related quality of life, as measured by increased AQLQ scores, observed during the parent study were maintained throughout TRAVERSE in the dupilumab/dupilumab group. In patients receiving placebo in...
the parent study, dupilumab treatment in TRAVERSE improved asthma control and asthma-related quality of life by Week 24 with further improvements seen by Week 48.

These effects were observed in both OCS dose subgroups.

<table>
<thead>
<tr>
<th>10–12</th>
<th>Reductions in OCS dose observed in VENTURE persisted through TRAVERSE.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The mean daily OCS dose and mean cumulative OCS dose were markedly higher in placebo/dupilumab treated patients compared with dupilumab/dupilumab treated patients regardless of OCS dose subgroup in both VENTURE and TRAVERSE. We note here that in TRAVERSE, modification of daily OCS dose was permitted at the discretion of the study investigator, but changes were not guided by a protocol-defined down-titration algorithm as in VENTURE.</td>
</tr>
<tr>
<td></td>
<td>Of the patients who achieved clinically relevant OCS dose thresholds of 0 mg per day, 5 mg or less per day and less than 10 mg per day at the end of VENTURE, 65 to 71% maintained this OCS dose target throughout the 48-week treatment period of TRAVERSE.</td>
</tr>
</tbody>
</table>

| 13    | In conclusion, dupilumab maintained the improvements in clinical outcomes, and reductions in OCS dose observed in the parent study throughout TRAVERSE regardless of baseline OCS dose. In patients on placebo in VENTURE who initiated dupilumab in TRAVERSE, rapid improvements in clinical outcomes were observed, which were sustained throughout TRAVERSE. |